French Childhood Cancer Survivor Study

  • participants needed
  • sponsor
    Institut National de la Santé Et de la Recherche Médicale, France
Updated on 8 November 2020


The FCCSS is a multicentric national large-scale collaborative population-based study of children treated for a solid tumor before 2000 in France and before the age of 19 years.

The study is concerned by improving knowledge about the long-term effects caused by cancer and its treatments including adverse health and social outcomes.

The main reason of the FCCSS is to estimate the risk of adverse health and social outcomes that may occur after a cancer treatment and to prevent them by providing adapted follow-up care.

The cohort will be followed for up to 20 years from 2011.


The main objectives of the FCCSS are to:

  • estimate the relationship between doses received (radiotherapy, chemotherapy) at a given organ and risk of second malignancy tumors;
  • help identify patients at higher risk;
  • compare the mortality occurred among the survivors with the general population;
  • investigate the consequences of various intensities of exposure to chemotherapy and/or radiation on health outcomes (such as cardiovascular, cerebrovascular and thyroid diseases, diabetes,);
  • characterize survivors with respect to socioeconomic status and quality of life.

The cohort will be ascertained using:

  • the medical records from the treatment centers in order to characterize the childhood cancer, estimate doses of radiotherapy received by all organs and measure the chemotherapy administered;
  • the French National Identification Registry and the French Death Registry in order to obtain the vital status and the causes of the deaths for the former patients
  • a self-questionnaire that covers the entire future of the survivors (e.g. social status, family network, fertile offspring, access to care, access to bank loans, occupation,...);
  • the French National Health Insurance Information System that contains data on all reimbursements for health expenditure including medicinal products as well as outpatient medical and nursing care, prescribed or performed by healthcare professionals.

In an initial cohort, we have already studied the iatrogenic effects of the cancer treatments. We have estimated the doses of ionising radiations delivered by radiotherapy to the target volume and by organs at distance. We found an important role of the radiotherapy and chemotherapy in the risk of a second cancer:

  • the cancers occuring after childhood cancer are in excess compared to the general population,
  • we studied the relationship between the brain radiation dose and the cerebrovascular mortality,
  • there is a high risk of cardiac pathology after anthracyclines administration for a childhood cancer,
  • cancer treatments increase the risk of second malignant neoplasms in digestive organs after a very long latency period,
  • the risk of thyroid adenoma increased with the radiation dose received by the thyroid during childhood cancer treatment, and plateaued at high doses,
  • there is a high long-term mortality risk for all types of second malignant neoplasms whatever the treatment received.

Condition Childhood Solid Tumor
Clinical Study IdentifierNCT01620372
SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last Modified on8 November 2020


Yes No Not Sure

Inclusion Criteria

All types of solid childhood cancer in France
Age at diagnosis: Below age 19
Period of diagnosis: between 1st January 1942 and 31st December 1999
Complete identification (first name, last name, date of birth and place of birth)

Exclusion Criteria

Leukaemia cases
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note